Bilia AB (publ) (FRA:BHJC)
Germany · Delayed Price · Currency is EUR 10.28
-0.10 (-0.96%)
Last updated: Jul 30, 2025
Blueprint Medicines Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 39,699 | 39,151 | 38,514 | 35,345 | 35,509 | 30,168 | Upgrade | |
Revenue Growth (YoY) | 2.44% | 1.65% | 8.97% | -0.46% | 17.70% | 2.24% | Upgrade |
Cost of Revenue | 33,197 | 32,728 | 32,368 | 29,287 | 29,464 | 25,168 | Upgrade |
Gross Profit | 6,502 | 6,423 | 6,146 | 6,058 | 6,045 | 5,000 | Upgrade |
Selling, General & Admin | 5,324 | 5,190 | 4,724 | 4,328 | 4,060 | 3,507 | Upgrade |
Other Operating Expenses | -36 | -7 | -23 | -5 | -23 | -6.1 | Upgrade |
Operating Expenses | 5,288 | 5,183 | 4,701 | 4,323 | 4,037 | 3,501 | Upgrade |
Operating Income | 1,214 | 1,240 | 1,445 | 1,735 | 2,008 | 1,499 | Upgrade |
Interest Expense | -434 | -420 | -341 | -175 | -155 | -148 | Upgrade |
Interest & Investment Income | 20 | 21 | 14 | 4 | 2 | 3 | Upgrade |
Earnings From Equity Investments | 57 | 46 | 88 | 89 | 55 | 46 | Upgrade |
Currency Exchange Gain (Loss) | -7 | -7 | -8 | -18 | 3 | -5 | Upgrade |
Other Non Operating Income (Expenses) | -9 | -8 | -11 | - | - | - | Upgrade |
EBT Excluding Unusual Items | 841 | 872 | 1,187 | 1,635 | 1,913 | 1,395 | Upgrade |
Merger & Restructuring Charges | -5 | -5 | -21 | -14 | -48 | -136.1 | Upgrade |
Impairment of Goodwill | - | - | - | - | -35 | - | Upgrade |
Gain (Loss) on Sale of Assets | 7 | 7 | 3 | 381 | - | 6 | Upgrade |
Asset Writedown | -10 | -10 | -10 | - | - | -5 | Upgrade |
Pretax Income | 833 | 864 | 1,159 | 2,002 | 1,830 | 1,260 | Upgrade |
Income Tax Expense | 192 | 202 | 228 | 380 | 373 | 276 | Upgrade |
Earnings From Continuing Operations | 641 | 662 | 931 | 1,622 | 1,457 | 984 | Upgrade |
Net Income | 641 | 662 | 931 | 1,622 | 1,457 | 984 | Upgrade |
Net Income to Common | 641 | 662 | 931 | 1,622 | 1,457 | 984 | Upgrade |
Net Income Growth | -17.82% | -28.89% | -42.60% | 11.33% | 48.07% | 21.93% | Upgrade |
Shares Outstanding (Basic) | 92 | 92 | 92 | 93 | 98 | 100 | Upgrade |
Shares Outstanding (Diluted) | 93 | 92 | 92 | 93 | 98 | 100 | Upgrade |
Shares Change (YoY) | 0.63% | 0.28% | -1.01% | -4.79% | -2.38% | -0.76% | Upgrade |
EPS (Basic) | 6.94 | 7.19 | 10.12 | 17.44 | 14.91 | 9.83 | Upgrade |
EPS (Diluted) | 6.90 | 7.16 | 10.10 | 17.41 | 14.90 | 9.83 | Upgrade |
EPS Growth | -18.42% | -29.11% | -41.99% | 16.85% | 51.56% | 22.89% | Upgrade |
Free Cash Flow | 114 | 333 | -498 | -862 | 730 | 1,583 | Upgrade |
Free Cash Flow Per Share | 1.23 | 3.60 | -5.40 | -9.26 | 7.46 | 15.80 | Upgrade |
Dividend Per Share | 5.600 | 5.600 | 6.600 | 8.800 | 8.000 | 6.000 | Upgrade |
Dividend Growth | -15.15% | -15.15% | -25.00% | 10.00% | 33.33% | - | Upgrade |
Gross Margin | 16.38% | 16.41% | 15.96% | 17.14% | 17.02% | 16.57% | Upgrade |
Operating Margin | 3.06% | 3.17% | 3.75% | 4.91% | 5.66% | 4.97% | Upgrade |
Profit Margin | 1.62% | 1.69% | 2.42% | 4.59% | 4.10% | 3.26% | Upgrade |
Free Cash Flow Margin | 0.29% | 0.85% | -1.29% | -2.44% | 2.06% | 5.25% | Upgrade |
EBITDA | 2,010 | 2,069 | 2,242 | 2,493 | 2,759 | 2,159 | Upgrade |
EBITDA Margin | 5.06% | 5.29% | 5.82% | 7.05% | 7.77% | 7.16% | Upgrade |
D&A For EBITDA | 796 | 829 | 797 | 758 | 751 | 660 | Upgrade |
EBIT | 1,214 | 1,240 | 1,445 | 1,735 | 2,008 | 1,499 | Upgrade |
EBIT Margin | 3.06% | 3.17% | 3.75% | 4.91% | 5.66% | 4.97% | Upgrade |
Effective Tax Rate | 23.05% | 23.38% | 19.67% | 18.98% | 20.38% | 21.91% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.